Use of triazoles for the treatment of invasive aspergillosis: A three-year cohort analysis

Matthew P. Cheng, José L. Orejas, Esther Arbona-Haddad, Tyler D. Bold, Isaac H. Solomon, Kaiwen Chen, Alisha Pandit, Amanda E. Kusztos, Kaelyn C. Cummins, Alexis Liakos, Francisco M. Marty, Sophia Koo, Sarah P. Hammond

Research output: Contribution to journalArticlepeer-review


In a 3-year cohort study of adult patients with proven or probable IA, fewer patients initially treated with isavuconazole experienced adverse events compared with voriconazole, but more patients required a change in therapy due to lack of clinical efficacy.

Original languageEnglish (US)
Pages (from-to)58-64
Number of pages7
Issue number1
StatePublished - Jan 1 2020
Externally publishedYes

Bibliographical note

Funding Information:
MPC receives salary support from a postdoctoral training grant, provided by the Fonds de recherche Santé Québec.

Funding Information:
These results were presented in abstract form at IDWeek 2018, Abstract #358. This manuscript was prepared as part of routine work. MPC, JLO, EAH, TDB, IHS, KCC, AP, AEK, KC and SK have no relevant disclosures to report. FMM has received research grant support from Ansun, Astellas, Cidara, Chimerix, F2G, Gilead, Merck, Shire and WHISCON and has received consulting honoraria from Alexion, Amplyx, Astellas, Basilea, Fate, GlaxoSmithKline, Merck, Pfizer, Roche Molecular diagnostics, Shire and United Medical. SPH has research funding from Merck and AiCuris.


  • Aspergillus
  • invasive aspergillosis
  • isavuconazole
  • posaconazole
  • voriconazole

PubMed: MeSH publication types

  • Journal Article

Fingerprint Dive into the research topics of 'Use of triazoles for the treatment of invasive aspergillosis: A three-year cohort analysis'. Together they form a unique fingerprint.

Cite this